Adenocarcinoma Clinical Trial
— SERPANOfficial title:
SERum-bank for PANcreatic Cancer
This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (<2cm), the chances of recovery are very good. But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. Today, there is no any effective means of detection... Blood markers can be a simple means of early detection
Status | Recruiting |
Enrollment | 400 |
Est. completion date | January 1, 2026 |
Est. primary completion date | January 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | ADENOCARCINOMA GROUP Inclusion Criteria: - Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis. - At the start of treatment (before surgery / 1st course of chemotherapy) - Age = 18 years - Patient affiliated or entitled to a social security system Exclusion Criteria: - Patient refusal - Acute renal failure - Child-Pugh B or C cirrhosis - Patient under guardianship or curators - Other synchronous cancer or history of cancer <5 years - Language barrier CONTROL GROUP Inclusion Criteria: - Age = 40 years - Patient affiliated or entitled to a social security system - Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease Exclusion Criteria: - Patient refusal - Acute renal failure - Child-Pugh B or C cirrhosis - Patient under guardianship or curators - Other synchronous cancer or history of cancer <5 years |
Country | Name | City | State |
---|---|---|---|
France | CHU Saint-Etienne | Saint-Étienne | |
France | Institut Cancérologique Lucien Newirth (ICLN) | Saint-Priest-en-Jarez |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Saint Etienne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum adiponectin concentration | Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%. | Months : 0 | |
Secondary | Serum CA19.9 concentration | Measure by blood sample result Threshold for Comparison of diagnostic performance compared to serum adiponectin concentration | Months : 0, 3, 6, 9, 12 | |
Secondary | Tumor response and progression rates according to RECIST v1.1 | Tumor response and progression rates defined according to RECIST v1.1 criteria according to a serum threshold of the prognostic biomarker to be identified by logistic regression analyzes. | Month 12 | |
Secondary | Progression-free survival | Months : 24 | ||
Secondary | Overall survival | Months : 24 | ||
Secondary | Serum adiponectin concentration | Measure by blood sample result Serum adiponectin concentration to correlate with cancer progression or not. | Months : 3, 6, 9, 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT02125240 -
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
|
Phase 3 | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
Completed |
NCT01579721 -
Prospective Randomized Study of SILS Versus CLS for Rectal Cancer
|
Phase 4 | |
Completed |
NCT01206530 -
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
Completed |
NCT00548548 -
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
|
Phase 3 | |
Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00183859 -
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
|
Phase 1 | |
Recruiting |
NCT01930864 -
Metformin Plus Irinotecan for Refractory Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02498860 -
Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung
|
Phase 2 | |
Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 |